Log in
Enquire now
‌

US Patent 10428120 Serum half-life extension using IgBD

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10428120
Date of Patent
October 1, 2019
Patent Application Number
15410363
Date Filed
January 19, 2017
Patent Citations Received
‌
US Patent 12084518 Trispecific binding proteins and methods of use
0
‌
US Patent 11623958 Single chain variable fragment CD3 binding proteins
0
‌
US Patent 11607453 Mesothelin binding proteins
0
‌
US Patent 11976125 B cell maturation antigen binding proteins
0
‌
US Patent 11535668 Inducible monovalent antigen binding protein
‌
US Patent 10844134 PSMA targeting trispecific proteins and methods of use
‌
US Patent 10849973 Prostate specific membrane antigen binding protein
‌
US Patent 10927180 B cell maturation antigen binding proteins
...
Patent Primary Examiner
‌
Phuong Huynh
Patent abstract

The present invention relates to complexes comprising (i) an immunoglobulin (Ig) binding moiety and (ii) a pharmaceutically active moiety, wherein the Ig binding moiety specifically binds to the constant domain 1 of the heavy chain (CH1) of an Ig molecule and their use for therapy and prophylaxis.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10428120 Serum half-life extension using IgBD

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.